Differential suppression of the tumorigenicity of HeLa and SiHa cells by adeno-associated virus

P-F Su\textsuperscript{1,2} and F Y-H Wu\textsuperscript{1}

\begin{itemize}
  \item \textsuperscript{1}Division of Cancer Research, Institute of Biomedical Sciences, Academia Sinica, Taipei 115; \textsuperscript{2}Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 110, Taiwan, Republic of China.
\end{itemize}

Summary Adeno-associated virus (AAV) is well known for suppression of oncogenesis in rodents, but its inhibitory effects on human carcinoma are less well understood. We report the differential ability of AAV to inhibit the tumorigenicity of two human cervical carcinoma cell lines. The wild-type AAV-2 DNA carried by a pSV2Neo vector was transfected into HeLa cells, which contain 50 copies of human papillomavirus type 18 (HPV-18), and SiHa cells, which contain 1–2 copies of HPV-16. About 1–3 copies of AAV genome were introduced per cell. AAV transfection moderately reduced the growth rate and anchorage-independent activity of the cells. In nude mice, the size of tumours arising from SiHa cells was reduced by 87%, in contrast to no reduction in tumour size arising from HeLa cells. This suggests that the differential suppression exerted by AAV may be due to differences in HPV copy number. To define the region that is responsible for the oncosuppression, mutation analyses were conducted. The results of nude mouse assays showed that both the replication gene and inverted terminal repeats of AAV were important for the inhibition. This study may provide a model system for further studies on the underlying mechanism of AAV oncosuppressive activity.

Keywords: adeno-associated virus; human papillomavirus; human cervical carcinoma cell lines; oncosuppression; nude mice

The parvoviridae family has been divided into three genera based on the requirement for helper viruses. Autonomous parvovirus and densovirus replicate autonomously, whereas dependovirus needs a helper virus for replication (Siegel et al., 1985). Autonomous virus and dependovirus interfere with both spontaneous oncogenesis and experiment-induced tumours in rodents (Rommelalere and Tattersall, 1990). The suppression is probably exerted through indirect, e.g. immune system or direct virus-host interactions (van Pachterbeke et al., 1993). The underlying mechanism is however still elusive.

Adeno-associated virus (AAV), a dependovirus, significantly inhibits carcinogenesis induced by adenovirus (Ad), herpes simplex virus, bovine papillomavirus (BPV) and the ras oncogene in rodents (Schlehofer, 1994). In humans, no known disease has been associated with AAV infection (Berns and Bohensky, 1987), although recent reports have shown a linkage of AAV infection to miscarriage in mice and humans (Botquin et al., 1994; Tobiasch et al., 1994).

Studies of the effects of AAV on human cancer cells have led to four main conclusions. (1) AAV infection reduces human tumour cell proliferation (Bantel-Schaal, 1990), disturbs the cell cycle (Winocour et al., 1988) and induces cell differentiation (Bantel-Schaal, 1995; Klein-Bauernschmitt et al., 1992). (2) Seroepidemiological studies have found that the incidence of AAV antibody are lower in cervical or prostate carcinoma patients than in controls (Georg-Fries et al., 1984; Mayor et al., 1976). (3) AAV infection has been reported to suppress the promoter activity of human papillomavirus type 16 (HPV-16) (Hermonat, 1994), while HPV is one of the potent inducers of cervical carcinoma (zur Hausen, 1994). (4) AAV infection inhibits in vitro cellular transformation of rodent cells mediated by BPV, which is a close relative to HPV (Hermonat, 1989). Taken together, it seems that AAV infection is reciprocally related to human cervical carcinoma. However, the inhibitory activity of AAV in human cells is less well understood than rodents. Nude mice assay has shown that the tumour growth rate induced by human cervical carcinoma HeLa cells was moderately reduced by AAV infection (Walz and Schlehofer, 1992). The issue of whether AAV can suppress the tumorigenicity of human cervical carcinoma cells was thus pursued in this study.

The human AAV type 2 DNA was cloned into a pSV2Neo vector (Southern and Berg, 1982) to generate a pAVNeo plasmid. The pSV2Neo or pAVNeo DNA was transfected into two cervical carcinoma cell lines, HeLa and SiHa. HeLa contains 10–50 copies of HPV-18 DNA (Schwarz et al., 1985) per cell and SiHa contains 1–2 copies of HPV-16 DNA (Baker et al., 1987) per cell. The cells were selected by genetin and expanded without cloning to avoid possible misleading conclusions derived from using a particular cloned cell. A mixed culture is also more similar to the in vivo condition than a cloned one. To assess whether the tumorigenicity of carcinoma cells can be affected by AAV transfection, a nude mouse assay was performed. The in vitro transformation properties including growth rate and anchorage-independent activity were compared in cells transfected with or without AAV. The AAV genome consists of a replication (rep) gene, a capsid (cap) gene (Srivastava et al., 1983) and two palindromic inverted terminal repeats (ITRs) (Lusby et al., 1980). To understand the control region for the oncosuppressive activity, the AAV genome was mutated. The data indicate that the rep gene and ITRs of AAV but not the cap gene are important for AAV's inhibitory activity.

Materials and methods

Cells

Human cervical carcinoma cell lines, HeLa and SiHa, were maintained in Dulbecco's modified Eagle medium (DMEM) and Earle's minimum essential medium (EMEM), respectively. All media were supplemented with 10% heat-inactivated (56°C, 30 min) fetal calf serum, non-essential amino acids, 0.03% L-glutamine and 50 μg ml\textsuperscript{-1} gentamycin.

Plasmids

In this experiment, the AAV DNA was introduced into cells in a recombinant plasmid form instead of virus. The
advantages of using a cloned AAV are that the pSV2Neo vector contains a neo gene by which the recombinant plasmid-harbouring cells can be selected after transfection; the recombinant plasmids are much easier to purify than the viruses, and the plasmid is less of a biohazard than the infectious viruses. The wild-type AAV-2 genome (4.7 kb) was obtained from the pAV1 plasmid (Laughton et al., 1983) by BgII and PvuII digestion. The left distal 1.0 kb of the rep gene was deleted by BamHI digestion to give a 3.7 kb fragment containing a truncated rep gene. Alternatively, part of the cap gene (1.1 kb) was deleted by Apal digestion to yield a 3.6 kb AAV fragment. This fragment was further digested by Msel to remove the 125 base ITRs at both ends generating a 3.35 kb fragment. The wild-type or mutated AAV DNA was then cloned into pSV2Neo vector at the BamHI site. The recombinant plasmids carrying wild-type AAV, truncated rep gene, truncated cap gene, or both cap and ITRs deleted insertions are designated pAVNeo, pAVR, pΔAV and pΔITR respectively (Figure 1). The plasmids were purified by alkaline lysis followed by caesium chloride ultracentrifugation (Sambrook et al., 1989).

**Transfection and selection**

The pSV2Neo vector, or one of the recombinant plasmids described above, was transfected into cells by the lipofection method (BRL). Briefly, cells at a density of about 80% confluency in a 60 mm dish were plated one day before transfection. DNA (5 μg) and lipofectin (20 μg), each in 100 μl of water, were mixed at room temperature for 15 min. The lipofectin–DNA mixture was added dropwise to the cells in Opti-medium (Gibco) and incubated at 37°C for 8 h. One day later, the transfected cells in a 60 mm dish were split into five 100 mm dishes. After 24 h, 1.5 mg ml⁻¹ genetic sulphate (G418; Gibco) at a concentration sufficient for 90% inhibition of cell growth (ID₅₀) within 3 days was applied to select for the plasmid-harbouring cells. Ten to 14 days after selection, the survival cells formed at least 50 colonies per 100 mm dish; these colonies were then pooled as a mixture culture and used in this experiment. The ID₅₀ (0.8 mg ml⁻¹) of G418 was subsequently employed to maintain the cells. HeLa cells transfected with pSV2Neo or pAVNeo are designated SVNeo-HeLa and AVNeo-HeLa respectively. Similarly, SiHa cells transfected with one of the aforementioned plasmids containing wild-type or mutated AAV are referred to as SVNeo-SiHa, AVNeo-SiHa, AVR-SiHa, ΔAV-SiHa or ΔITR-SiHa.

**Determination of AAV copy number in cells**

The AAV copy number in cells was determined by slot-blot analysis. Various amounts of the 4.7 kb AAV DNA were loaded onto nylon membrane and hybridised with a ³²P-labelled AAV probe. The resultant radioactivity was plotted against AAV copy number to generate a standard curve. The radioactivity obtained from the genomic DNA was interlepted into the standard curve to yield the AAV copy number. The copy number per cell was calculated by normalising the genomic DNA amounts into cell numbers.

**Detection of AAV DNA replication**

Monolayer cells in a 100 mm dish were infected with adenovirus type 5 (Ad 5) (2.3 × 10⁶ virus particles). Two days after infection, cells were lysed by 2.5 ml of Hirt's solution [10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.1 M sodium chloride and 1% sodium dodecyl sulfate (SDS)] and the lysate was passed through a glass wool column to remove the cellular DNA. The flow-through containing the viral DNA was treated with 200 μg ml⁻¹ proteinase K, extracted with phenol–chloroform, and analysed in a 1% agarose gel. The DNA was then transferred to nitrocellulose paper and hybridised with a ³²P-labelled AAV probe.

**Assay of tumorigenicity in vivo**

Tumorigenicity of cervical carcinoma cells was assayed in 4- to 6-week-old female athymic nude mice. Cells suspended in 0.1 ml of phosphate-buffered saline (PBS) were injected subcutaneously near the shoulders of the mice. The size of tumour in situ was measured in three dimensions at various times after injection. Animals were sacrificed when the tumour grew to more than 1 cm in diameter or 2 months later, whichever came first.

**Results**

**Detection of integrated AAV DNA in HeLa and SiHa cells**

The AAV genome usually integrates into the host chromosome during latent infection; it can be 'rescued' and undergoes replication upon superinfection with a helper virus (Samulski et al., 1982). To examine whether the recombinant AAV plasmids were integrated into cell chromosomes, the AAV-transfected cells were infected with Ad 5 helper viruses. Figure 2 shows that the wild-type replicative form (RF) and its dimer form were observed in both AVNeo-HeLa and AVNeo-SiHa cells (Figure 2a and b, lane 3). The replication products were absent from both parental and SVNeo-HeLa (Figure 2a, lanes 1 and 2) and from both parental and SVNeo-SiHa cells (Figure 2b, lanes 1 and 2). These results suggest that the transfected AAV DNA sequences remain integral so that they can be rescued by helper virus in HeLa and SiHa cells. On the other hand, no AAV DNA was observed from AVNeo-HeLa or AVNeo-SiHa cells without Ad 5 infection (data not shown). These findings imply that most of the AAV DNA may integrate into host cell chromosomes, whereas the AAV DNA remaining in an episomal form may be rare. The issue of whether the AAV DNA integrates into cell chromosomes at a specific site as described by others (Kotin et al., 1992; Walz and Schlehofer, 1992) remains unresolved.

The existence of mutant AAV DNA in SiHa cells was also examined by Ad 5 rescue assay. Owing to the deletion of a 1.1 kb fragment of the cap gene, the RF size in ΔAV-SiHa was 3.6 kb whereas no single-stranded (s.s.) DNA could be
found (Figure 2b, lane 5). The data agree with those of other researchers (Hermonat et al., 1984) who reported that deletion in the cap gene exerts no effect on AAV replication but reduces the accumulation of s.s. DNA. It has been reported that the rep gene and the ITRs are required for the rescue of AAV DNA and AAV DNA replication (Senapathy et al., 1984; Samulski et al., 1983). These conclusions are further extended by our studies. The replication products were absent in both AVR-SiHa cells in which the rep gene was truncated (Figure 2b, lane 4) and ΔITR-SiHa cells in which both ITRs were deleted (Figure 2b, lane 6). The existence of these two mutated AAV genomes in cells was proven by slot blotting as shown in Figure 3.

Effect of AAV on the in vivo tumorigenicity of HeLa and SiHa cells

To determine whether AAV transfection affects the in vivo tumorigenicity of human cervical carcinoma cells, HeLa and SiHa cells transfected with or without AAV plasmids were injected into nude mice and the sizes of the resulting tumours were measured. The data reveal that the mean sizes of tumours arising from parental, SVNeo-, and AVNeo-HeLa cells were 58.7 ± 6.435 ± 2.442.8 ± 8.0 mm³ respectively, indicating that the tumorigenicity of HeLa cells was not affected by AAV transfection.

Figure 4 shows that the tumours derived from SVNeo-SiHa cells appeared later than those derived from SiHa cells, yet by day 40 the tumour sizes from both cell lines were similar. The sizes of tumours of the parental and SVNeo-SiHa cells were 62.0 ± 54.0 mm³ respectively. The relative sizes of tumours from AVNeo-SiHa (8.0 mm³) and ΔAV-SiHa (4.5 mm³) cells decreased noticeably to 13% and 7% respectively, whereas the sizes of tumours arising from AVR-SiHa (115.5 mm³) and ΔITR-SiHa (92.8 mm³) were much larger as compared with those of the tumours from parental SiHa cells. These results suggest that the tumorigenicity of SiHa cells was suppressed by the presence of wild-type AAV. Mutation of the rep gene or ITR abolishes the oncosuppressive activity of AAV, whereas deletion of the cap gene exerts no effect.

Effect of AAV on the growth rate and anchorage-independent activity of SiHa cells

The effects of AAV on the in vitro biological properties of cells were examined by measuring cell proliferation activity and the ability to form colonies in soft agar. Figure 5 shows that HeLa and SiHa cells had similar growth rates between the parental and transfected cells (Figure 5a and b). Table I reveals that relative colony formation efficiency was decreased in AVNeo-HeLa cells as compared with that of parental HeLa cells, yet the degree of reduction was similar to that of SVNeo-HeLa. In SiHa cells, the efficiency of AVNeo-SiHa cells was about half that of parental SiHa cells. The efficiency of SVNeo-SiHa cells, however, was only about 66% that of parental cells, indicating that the changes in efficiency due to the presence of AAV were slight.

The reasons accounting for the mild changes may be that oncogenesis is believed to be a multiple-step process: normal cells escape from cell senescence, lose tumour-suppressor genes, activate oncogenes and then become tumorigenic. In the present model system, AAV probably reverses the transformation properties of SiHa cells from tumorigenic to non-tumorigenic with no further conversion.

Discussion

This report describes the differential responsiveness of two human cervical carcinoma cell lines to AAV DNA
transfection. The results of in vivo nude mice assays suggest that the tumorigenic phenotype of SiHa cells but not that of HeLa cells is significantly inhibited in the presence of AAV, although the existence of AAV DNA in both cell lines was proven by Ad 5 rescue assay.

The mechanism of AAV’s differential suppression is still not understood. However, the copy ratio of AAV to HPV in cells may play an important role. Since the AAV DNA molecules were found to be approximately 1–3 per transfected cells, the ratio of AAV to HPV in HeLa and SiHa is then deduced to be 1–3/50 and 1–3/1–2 respectively. HPV is one of the possible inducers of cervical carcinoma and its E6 and E7 gene products are known to be associated with HPV’s transformation activity. The inhibitory activity of AAV has been proposed to be exerted via the suppression activity of rep gene products on viral promoters containing Sp1 sequences (Hermonat, 1991). The Sp1 element has been found in the E6/E7 promoter of HPV-16 (Gloss and Bernard, 1990) and recent reports show that the promoters of HPV-16 (Hermonat, 1994) and HPV-18 (Horner, 1995) are repressed by AAV. Our immunoprecipitation analysis also showed that AAV transfection reduced the amount of E7 protein by 33% in SiHa cells (P-F Su and F Y-H Wu, manuscript in preparation). We therefore propose that a low copy number of the AAV genome is unable to overcome a large amount of HPV gene products in HeLa cells. On the contrary, AAV may probably compromise the low amount of HPV gene products in SiHa cells, thus exerting an oncosuppressive effect. A recent study (Walz and Schlehofer, 1992) has shown that the growth rate of tumours induced by HeLa cells is reduced by AAV infection. Since DNA transduction efficiency of virus infection is higher than that of DNA transfection, it may be that more AAV DNA molecules were introduced into HeLa cells during the experiment. The tumorigenicity of HeLa cells is therefore partially suppressed. Our preliminary results (P-F Su and F Y-H Wu, manuscript in preparation) have shown that increasing AAV copy number by cloning the AAV DNA into an episomal form Epstein–Barr virus-based vector can reduce the tumorigenicity of HeLa cells. It supports our ‘copy number hypothesis’ that the more AAV DNA being introduced or the higher AAV gene expression can exert, the higher AAV’s inhibitory activity.

Several other factors may also contribute to the observed differential inhibition by AAV in our study. The integration site of a cloned AAV DNA and the correlation between the integration site and the oncosuppressive activity is still elusive. The resolution of whether the differential suppression is caused by different integration awaits further studies. The difference of HPV type between cells, the differentiation state of cells and the expression activity of the rep gene in SiHa and HeLa cells may also affect the suppressive activity of AAV in cells.

To define the control motifs, various deletion mutants of the AAV genome were constructed as shown in Figure 1. The in vivo tumorigenicity assay revealed that very small tumours formed in nude mice that were injected with SiHa cells transfected either with wild-type or with cap gene-deleted AAV DNA. In contrast, when the rep gene was truncated by deleting the left-end 1 kb or when both ITRs of AAV genome were removed, the oncosuppressive activity of AAV was abolished (Figure 5). These data clearly demonstrate that an intact rep gene and ITRs, but not an intact cap gene, are required for the oncosuppressive effect of AAV. The requirement of the rep gene or its products for oncosuppressive activity agrees with previous studies (Hermonat, 1989; Yang et al., 1992) that have demonstrated that the rep gene is directly related to AAV’s suppression of cellular transformation. ITRs have been reported to have enhancer activity (Beaton et al., 1989); deletion of ITR may reduce the expression of the rep gene leading to the loss of AAV’s

Table 1 Anchorage-independent activity of the parental, pSV2Neo-, and pAVNeo-transfected HeLa or SiHa cells

| Cell                | No. of colonies | Relative efficiency |
|---------------------|----------------|---------------------|
| HeLa                | 404 ± 40.6     | 100.0               |
| SVNeo-HeLa          | 359 ± 33.4     | 88.9                |
| AVNeo-HeLa          | 317 ± 13.9     | 78.5                |
| SiHa                | 703 ± 50.2     | 100.0               |
| SVNeo-SiHa          | 425 ± 18.5     | 60.5                |
| AVNeo-SiHa          | 337 ± 4.8      | 47.9                |

*The procedures used are those of Adams (1980) with some modifications. In a 60 mm dish, 1.5 ml of the cell suspension was plated in agar medium layer (4.5 × 10⁶ for HeLa or 3 × 10⁵ for SiHa) in 0.3% agar medium. After plating, HeLa cells were incubated for 8 days and SiHa cells for 10 days. The colonies were stained with 1 ml of 0.05% p-dimontorotetrazolium violet dye. Mean value ± s.e. The data presented are one of three independent assays.

Figure 5 Comparison of the growth rate of parental, pSV2Neo- and pAVNeo-transfected HeLa (a) or SiHa (b) cells. Cells (1.0 × 10⁶ for HeLa or 2.0 × 10⁵ for SiHa) were plated into a 35 mm dish and were cultured in medium with 2% fetal calf serum. Cell number was counted daily for 5 days.
suppressive activity. On the other hand, ITR is needed for AAV DNA integration. Deletion of one or both ITRs may lead to an improper integration and deactivate the inhibitory function of AAV. Our results further indicate that mutation within the rep gene or ITR not only abolishes the inhibitory effect of AAV but also enhances the tumorigenicity of cancer cells. These observations point out the importance of the integrity of AAV sequence in its therapeutic applications.

The differential inhibitory effect of AAV on the tumorigenicity of HeLa and SiHa cell observed in this study has shed light on the interaction between AAV and HPV. This system can serve as a model to further elucidate the oncosuppressive mechanism of AAV, knowledge of which is a prerequisite for understanding the process of carcinogenesis and using AAV as an agent for gene therapy.

Acknowledgements

We express our sincere appreciation to Dr. Ming-Ta Hsu, our former colleague at the Institute of Biomedical Sciences (IBMS), for providing the plasmid pAVI and for valuable and constructive discussion. We also thank Dr. C.Y. Yu for the SiHa cell line and Catherine Fletcher for reading the manuscript. This work was supported by grant NSC3-0203-B-001-102 from the National Science Council of the Republic of China.

References

ADAMS RLP. (1980). Cell culture for biochemists. In Laboratory Techniques in Biochemistry and Molecular Biology. Work TS and Burdon RH (eds.) pp. 102–103. Elsevier/Northern-Holland Biomedical Press.

BAKER CC, PHELPS WC, LINGREN V, BRAUN MJ, GONDA MA AND HOWLEY PM. (1987). Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol., 61, 962–971.

BANTJEL-SCHAAU U. (1990). Adeno-associated paroviruses inhibit growth of cells derived from malignant human tumors. Int. J. Cancer, 45, 190–194.

BANTJEL-SCHAAU U. (1995). Growth properties of a human melanoma cell line are altered by adeno-associated parovirus type 2. Cancer, 77, 265–267.

BEATON A, PALUMBO P AND BURNS KI. (1989). Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein. J. Virol., 63, 4450–4454.

BERNS KI AND BOHENSKY RA. (1987). Adeno-associated viruses: An update. Adv. Virus Res., 32, 243–306.

BOTUQUIN V, CIDARREGUI A AND SCHLEHOFER JR. (1994). Adeno-associated virus type 2 interferes with early development of mouse embryos. J. Gen. Virol., 75, 2655–2662.

BEGOR-FRIES B, BIEDERLACK S, WOLF J AND ZUR HAUSEN H. (1984). Analysis of proteins, helper dependence, and seroepidemiology of a new human parovirus. Virology, 134, 64–71.

GLOESS B AND BERNARD H-U. (1990). The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. J. Virol., 64, 5577–5584.

HERMONAT PL. (1989). The adeno-associated virus Rep78 gene inhibits cellular transformation induced by bovine papillomavirus. Virology, 172, 253–261.

HERMONAT PL. (1991). Inhibition of H-ras expression by the adeno-associated virus Rep78 transformation suppressor gene product. Cancer Res., 51, 3373–3377.

HERMONAT PL. (1994). Adeno-associated virus inhibits papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res., 54, 2278–2281.

HERMONAT PL, LABOW MA, WRIGHT R, BURNS KI AND MUZYCZKA N. (1984). Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J. Virol., 51, 329–339.

HORER M, WEGER S, BENTZ K, HOPPE-SEYLER F, GEISEN C AND KLEIN-SCHMIDT JA. (1995). Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J. Virol., 69, 5485–5496.

KLEIN-BAUER FR, ZUR HAUSEN H AND SCHLEHOFER JR. (1992). Induction of differentiation-associated changes in established human cells by infection with adeno-associated virus type 2. J. Virol., 66, 4191–4200.

KOTIN RM, LINDEN RM AND BURNS KI. (1992). Characterization of a potential origin on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J., 11, 5071–5078.

LAUDHLIN CA, TRATSCINH JD, COON H AND CARTER BJ. (1983). Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene, 23, 65–73.

LUSBY E, FIFFE KH AND BURNS KI. (1980). Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J. Virol., 34, 402–409.

MAYOR HD, DRAKE S, STAHMANN J AND MUMFORD DM. (1976). Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am. J. Obstet. Gyn., 126, 100–104.

ROMMELAERE J AND TATTERSALL P. (1990). Oncosuppression of paroviruses. In Handbook of Paroviruses, Tijssen P (ed.) pp. 41–57. CRC Press Inc: Boca Raton, FL.

SAMBUROO J, FFRITSCH EF AND MANATISSI T. (1989). Molecular Cloning: A Laboratory Manual. (2nd ed.) pp. 1.21–1.52. Cold Spring Harbor Laboratory Press: New York.

SAMULSKI RI, BURNS KI, TAN M AND MUZYCZKA N. (1982). Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl Acad. Sci. USA, 79, 2077–2081.

SAMULSKI RJ, SRIVASTAVA A, BURNS KI AND MUZYCZKA N. (1983). Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell, 33, 135–143.

SCHLEHOFER JR. (1994). The tumor suppressive properties of adeno-associated viruses (Review). Mutat. Res., 305, 303–313.

SCHWARZ E, FRESEE UK, GISSMANN L, MAYER W, ROGGENBUX B, STREMLAU A AND ZUR HAUSEN H. (1985). Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature, 314, 111–114.

SENAPATHY P, TRATSCINH JD AND CARTER BJ. (1984). Replication of adeno-associated virus DNA. Complementation of naturally occurring rep-mutants by a wild-type genome or an ori-mutant and correction of terminal palindrome deletions. J. Virol., 60, 1–20.

SIEGL G, BATES RC, BURNS KI, CARTER BJ, KELLY DC, KURSTAK E AND TATTERSALL P. (1985). Characteristics and taxonomy of paroviridae. Intervirology, 23, 61–73.

SOUTHERN PJ AND BERG P. (1982). Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet., 1, 327–341.

SRIVASTAVA A, LUSBY EW AND BURNS KI. (1983). Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol., 45, 555–564.

TOBIAESCH I, RABREAU M, GELENETEKY K, LARUECHLARUS S, SEVERIN F, BECKER N AND SCHLEHOFER JR. (1994). Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion. Microbiol. Cell Biol., 44, 222.

VAN PACTHERBEKE C, TUYNDER M, COSYN JP, LESPARNARD L, LARISMONT D AND ROMMELAERE J. (1993). Parovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int. J. Cancer, 55, 672–677.

WALZ C AND SCHLEHOFER JR. (1992). Modification of some biological properties of HeLa cells containing adeno-associated virus DNA integrated into chromosome 17. J. Virol., 66, 3090–3002.

WINGCOUR E, CALLAHAM MF AND HUBERMAN E. (1988). Perturbation of the cell cycle by adenovirus-associated virus. Virology, 167, 393–399.

YANG Q, KADAM A AND TREMEPP JR. (1992). Mutational analysis of the adeno-associated virus rep gene. J. Virol., 66, 6058–6069.

ZUR HAUSEN H. (1994). Molecular pathogenesis of cancer of the cervix and its causation by specific HPV types. Curr. Top. Microbiol. Immunol., 186, 131–156.